ERO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ERO is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has strong upside history and solid revenue growth, but current price action is weak, analyst views are mixed-to-cautious, and the name is sitting near support ahead of earnings. Since the user wants an immediate decision and is unwilling to wait for a better entry, my direct view is: do not buy now; wait for a stronger post-earnings setup or a confirmed trend reversal.
The technical picture is mixed to bearish. MACD histogram is below zero and expanding negatively, which points to weakening momentum. RSI_6 at 23.57 is deeply oversold, but not yet a reliable bullish reversal signal by itself. Moving averages are converging, suggesting compression before a move, but there is no confirmed uptrend. Price at 25.83 is basically on the S1 support at 25.8, with S2 at 24.595 below and resistance first at 27.752 (pivot), then 29.703. The short-term pattern data suggests a modest next-week bounce potential, but the one-month estimate remains negative. Overall: near support, but no strong technical buy signal.
Revenue in Q4 2025 surged 161.27% YoY, and gross margin improved sharply to 51.36%, which shows strong operating leverage and healthier unit economics. The upcoming QMAR 2026 earnings on 2026-05-04 could act as a catalyst if the company beats expectations. Options sentiment is strongly bullish. Recent price target raises earlier in the year also show that some analysts still see upside.
Net income and EPS fell sharply year over year in the latest quarter, so profitability growth did not keep pace with revenue growth. Goldman Sachs downgraded the stock to Neutral and cut its target, citing weaker operational momentum, limited copper upside, and valuation concerns. BofA also downgraded it after weaker guidance. There is no recent news flow to support the stock, and the technical trend is still weak.
Latest quarter: 2025/Q4. Revenue rose to 320.15M, up 161.27% YoY, which is very strong top-line growth. Gross margin improved to 51.36%, up 20.17% YoY, showing better operating efficiency. However, net income fell to 76.97M and EPS dropped to 0.74, both down over 257% YoY, indicating that earnings quality was weaker despite the revenue surge. For a long-term investor, the growth is attractive, but the profit trend is not yet clean enough to justify an aggressive immediate buy.
Analyst sentiment has turned more mixed recently. Positive notes include Canaccord keeping Buy and lifting its target to C$51, Scotiabank raising to C$50 with Outperform, and Freedom Capital raising its target sharply. However, Goldman Sachs downgraded ERO to Neutral from Buy and cut its target to $31, citing reduced risk-reward appeal, valuation concerns, and operational uncertainty. BofA also downgraded to Neutral after weaker guidance. Net takeaway: Wall Street still has bulls, but the pros and cons view is now split, with the caution side gaining weight.
